News

[Please click on the title to view]

hI Argenol Product Launch 19.07.10
Pre close Trading Update 13.07.10
Term Loan Agreement 30.06.10
LTIP Awards
Plethora Products “Showcased” at The American Urological Association Annual Meeting
AGM Notice 2010 - 20.05.2010
Commercial Update TUCL 17.05.2010
£550,000 Placing 05.05.10
New Product Distribution Agreement: Hyalofemme
Preliminary Results For Financial Year Ended 31 December 2009
Notice of Results – 23rd Feb 2010
Pre-Close Trading Update

Result of General Meeting	7th Dec 2009
Dianatal Licensing Agreement	30th Nov 2009
Striant SR Licensing Agreement	23rd Nov 2009
Placing of New Shares and Issue of Convertible Loan Note	18th Nov 2009
PSD506: Cinical Update	30th Sep 2009
Holdings in the Company	7th Aug 2009
Holdings in the Company	5th Aug 2009
PSD502 for Premature Ejaculation Positive Outcomes from Final Phase III Pivotal Trial	29th Jul 2009
PSD503: Development Update	16th Jul 2009
AGM Statement and Trading Update	25th Jun 2009
Holdings in the Company	15th Jun 2009
Notice of AGM and Annual Report Publication	29th May 2009
Board Changes	26th May 2009
Global Agreement for PSD502, Financial Restructuring and 2008 Preliminary Results	26th May 2009
Premature Ejaculation Spray Enables Men to Last Six Times Longer after Penetration	2nd Apr 2009
Amendment to US License Agreement for PSD502 for Premature Ejaculation	1st Apr 2009
Board Changes	19th Feb 2009
Clinical Update: PSD502 for Premature Ejaculation Completion of Recruitment for Global Phase III Programme	17th Feb 2009
Result of General Meeting	16th Feb 2009
Subordinated Loan Facility Agreement with Sciele Pharma, Inc.	16th Feb 2009
Financing Update	22nd Jan 2009

Holdings in the Company	23rd Dec 2008
Holdings In the Company	18th Dec 2008
Holdings in the Company	11th Dec 2008
Additional Funding of £1m	8th Dec 2008
Clinical Update: Final Analysis PSD502 for Premature Ejaculation	8th Dec 2008
Holdings in the Company	14th Nov 2008
Clinical Update: New Study Confirms the Role of ErecAid as First Line Treatment for Erectile Dysfunction	14th Nov 2008
Clinical Update: Positive Outcomes from PSD502 EU Phase III Pivotal Trial	7th Nov 2008
Plethora Solutions 2008 Interim Results	30th Sep 2008
Clinical Update: Completion of European Phase III Trial of PSD502 for Premature Ejaculation	30th Sep 2008
Board Change	8th Aug 2008
Share Options Award	1st Jul 2008
Change of NOMAD	1st Jul 2008
Board Change	27th Jun 2008
AGM Statement	23rd Jun 2008
Clinical Update: Recruitment into the European Phase III Study into PSD502 is Complete	19th Jun 2008
Notice of AGM and Annual Report Publication	22nd May 2008
Preliminary Results for the year to 31 December 2007	29th Apr 2008
Clinical Update: PSD508 for Dysmenorrhoea Completion of Recruitment in Phase IIb Trial	24th Apr 2008
Notice of Preliminary Results	21st Apr 2008
Plethora Sign a $25m Revenue Interest Financing Agreement with Paul Capital Healthcare	1st Apr 2008
Clinical Update Positive Clinical Data from PSD506 Incontinence Study	5th Feb 2008
Change of Registered Office	10th Jan 2008

Clinical Update PSD502 for Premature Ejaculation European Phase III Study Underway	19th Dec 2007
Clinical Update PSD508 for Dysmenorrhea Phase IIb Trial Initiated and First Patients Recruited	6th Dec 2007
Clinical Update Positive Phase II Clinical Data for PSD503 in the Treatment of Stress Urinary Incontinence	29th Nov 2007
Clinical Update Initiation of the PSD502 Phase III Program for the treatment of Premature Ejaculation	30th Oct 2007
Clinical Update Final Analysis of the PSD597 Phase II Clinical Trial for the treatment of Interstitial Cystitis	8th Oct 2007
Plethora Solutions 2007 Interim Accounts	26th Sep 2007
Clinical Update Positive Outcome for Phase II Study of PSD597 for Interstitial Cystitis	6th Sep 2007
Clinical update PSD502 First line therapy in premature ejaculation	12th Jul 2007
Invicor update US phase III to start before year end and £4m loan secured from ETV	2nd Jul 2007
Completion of Recruitment in PSD597 Clinical Study	25th Jun 2007
Preliminary Results for the year to 31 December 2006	30th May 2007
PSD502 Licensing Agreement	24th May 2007
Timm Medical Acquires Marketing rights to Two Additional Products	8th May 2007
Clinical Update PSD510 Invicorp for erectile dysfunction	26th Feb 2007
Clinical Update PSD502 for premature ejaculation	22nd Feb 2007
Clinical Programme Extension Parallel Study PSD597 Analgesic Therapy Urogynaecological	8th Feb 2007

Product Update: Obson Erecaid Final	4th Dec 2006
Product Update: PSD401 Final	24th Nov 2006
OsbonErecAid: RFDA Allows Labeling for Use of ErecAid.pdf	9th Oct 2006
Plethora Solutions Receives £510,000	25th Sep 2006
Clinical Update: Erecaid PR	22nd Aug 2006
New Appointment	22nd Aug 2006
Dr E Versi appointed Senior Vice President Clinical Development	10th Aug 2006
Topical Analgesic Spray Clinical Study front line therapy	7th Aug 2006
Genito urinary compounds delivery technology licensed funded via novel	22nd Jun 2006
Maelor and Plethora Solutions licensing agreement micelle nanotechnology	1st Jun 2006
Preliminary Results for Year End 31 December 2005	4th Apr 2006
FDA Acceptance for Phase II Clinical Trial with PSD597	2nd Mar 2006
Proposed Acquisition Timm Medical Technologies	13th Feb 2006
Result of Extraordinary Meeting EGM	6th Feb 2006

Final Analysis Positive Phase II Clinical Study PSD502	16th Dec 2005
Positive Phase II Clinical Study PSD502	1st Dec 2005
InterimReport	28th Sep 2005
Interim results six months ended 30 June 2005	26th Sep 2005
Plethora Acquires new product treatment Interstitial Cystitis	26th Sep 2005
Completion of Recruitment PSD502 Phase II Clinical Study	19th Sep 2005
Clinical Update PSD50 Clinical plastic surgery burns	26th Jul 2005
Sexual Activity Monitor Collaborative Agreement	13th Jul 2005
Clinical Update PSD401 Sexual Activity Monitor SAM	22nd Jun 2005
Directors Dealings	19th May 2005
Plethora licenses Roche overactive bladder	18th Apr 2005
Plethora Solutions Holdings Plc First Day Dealings AIM	24th Mar 2005
Admission 170305	17th Mar 2005

View News In:

News Archive 2009